LDN in Clinical Practice - Andrew McCall, MB, ChB, DFM (2021 Conference) (LDN, low dose naltrexone)

Use of LDN for Chronic Pain - Sahar Swidan, PHARM.D., ABAAHP, FAARFM, FACA (2021 Conference) (LDN, low dose naltrexone)

This talk is on the use of LDN for chronic pain. She reviews LDN’s actions in the CNS and the PNS, the immunomodulating effect of LDN, and some clinical trials on the use of LDN.

The Use of LDN for Ophthalmic Conditions - Sebastian Denison, Pharm (2021 Conference) (LDN, low dose naltrexone)

This talk is about how they utilize LDN, their LDN protocol, and their outcomes and expectations. The information presented about humans can apply to animals as well.

The LDN Side Effect Survey Results from 2020 - Jill Brook, MA (2021 Conference) (LDN, low dose naltrexone)

Jill Brook, MA is a Research Advisor to the LDN Research Trust. In this presentation she shares the results of the 2020 LDN Side Effect Survey.

The EMF Toxicity Epidemic - Protection and Treatment - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Longevity - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Hypothyroidism - Dawn Ipsen, PharmD (2021 Conference) (LDN, low dose naltrexone)

Dr. Dawn Ipsen is a compounding pharmacist who presents on some roles low dose naltrexone (LDN) may have in helping patients with hypothyroidism. She discusses hypothyroidism, its prevalence, and treatment goals. 

Developing outcome centric, territory-specific access protocols for the provision of niche product - John Bardsley (2021 Conference) (LDN, low dose naltrexone)

John Bardsley is managing director of Thistle Pharma Ltd. LDN is an unlicensed medicine. Much of what he is talking about pertains specifically to the UK sector, and may apply to your own territories as well.

Autoimmune thyroiditis Part 3 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 3 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness. This last segment will bring it all together and give practical ways to use this information. 

Autoimmune thyroiditis Part 2 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 2 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness